EUVIMEDEUVIMED entdecken
Open Access

Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model

A Young Park, Ju Hee Kim, Sangeun Lee, Hoe Suk Kim, Hong Kyu Kim, Han-Byoel Lee, Wonshik Han

International Journal of Oncology · 2025

DOI: 10.3892/ijo.2025.5760 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Oncology, 2025. Verfasst von A Young Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‑negative breast cancer (TNBC) is a lethal subtype of breast cancer with a poor prognosis and limited existing treatment options. The immune checkpoint inhibitor, anti‑programmed death ligand 1 (PD‑L1), has recently emerged as a promising alternative in treating TNBC. PD‑L1 is critical in tumor immune evasion and is therefore a key target for cancer immunotherapy. Although anti‑PD‑L1 therapy is effective in breast cancer based on clinical trials, the relationship between PD‑L1 expression levels and treatment response remains unclear. To investigate this, a 4T1 breast cancer cell line that stably overexpressed PD‑L1 was established and was used to create a tumor model in mice. Mice were treated with anti‑PD‑L1 antibodies, and tumor growth was compared between the control and treated groups. PD‑L1 overexpressing tumors did not exhibit an antitumor response to anti‑PD‑L1 therapy compared with the control tumors. Additionally, immune cell infiltration and activation were significantly altered, as shown by immunohistochemical staining and bulk RNA sequencing. In PD‑L1‑overexpressing tumors that did not respond to treatment, immune cell markers and antitumor immune pathways were downregulated. These results demonstrated that excessive PD‑L1 expression creates an immunosuppressive tumor microenvironment, which impairs the efficacy of anti‑PD‑L1 therapy. The present study suggests that excessive PD‑L1 expression reduces the effectiveness of antitumor immunotherapy, and that PD‑L 1 expression levels are essential in predicting the response to antitumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsB7-H1 AntigenImmune Checkpoint InhibitorsAnimalsMiceFemaleCell Line, TumorHumansUp-RegulationDisease Models, AnimalGene Expression Regulation, NeoplasticTumor MicroenvironmentMice, Inbred BALB C

Stichwörter der Autor:innen

immune check point inhibitorprogrammed death ligand 1triple‑negative breast cancertumor microenvironment

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCd274 protein, mouseCD274 protein, human

Autor:innen und Institutionen

  • Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea.

Zitieren

APA

Park, A. Y., Kim, J. H., Lee, S., Kim, H. S., Kim, H. K., Lee, H. B., & Han, W. (2025). Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model. International Journal of Oncology. https://doi.org/10.3892/ijo.2025.5760

Vancouver

Park AY, Kim JH, Lee S, Kim HS, Kim HK, Lee HB, et al. Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model. International Journal of Oncology. 2025. doi:10.3892/ijo.2025.5760

BibTeX
@article{Park2025,
  author = {Park, A Young and Kim, Ju Hee and Lee, Sangeun and Kim, Hoe Suk and Kim, Hong Kyu and Lee, Han-Byoel and Han, Wonshik},
  title = {Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model},
  journal = {International Journal of Oncology},
  year = {2025},
  doi = {10.3892/ijo.2025.5760}
}
Kostenlos starten →